Bacterial Sepsis Treatment & Management
- Author: Burke A Cunha, MD; Chief Editor: Michael Stuart Bronze, MD more...
Surgical Intervention
Early evaluation by a surgeon for patients with presumed intra-abdominal or pelvic sepsis is essential, because surgical intervention may be required for cure or resolution of the infection. For example, peritonitis may result in abscesses, which may subsequently need to be drained. Inadequate correction of intra-abdominal perforation or drainage procedures may result in a continuance or relapse of the patient’s septic condition.
The procedures used are dependent on the source of the infection, the severity of the sepsis, the patient’s clinical status, among other factors in individual scenarios.
Coordinate surgical follow-up with the surgeon.
Consultations
Obtain a consultation with a surgeon for patients with presumed intra-abdominal or pelvic sepsis. Early surgical consultation and involvement by the surgical team is essential, because many causes of sepsis involve a perforated viscus, abscess, or obstructing process that requires surgical intervention for cure or resolution of the infection.
Also obtain a consultation with an infectious disease specialist for all patients with sepsis included in the differential diagnosis.[31]
Approach Considerations
Early and aggressive medical therapy is indicated in patients with suspected sepsis.[28, 29, 30, 31, 32, 33, 34, 35, 36, 37] However, it is crucial to consider pseudosepsis as a cause of the presenting syndrome complex because most causes of pseudosepsis are readily treatable and reversible if recognized and treated early. Patients with pseudosepsis require supportive therapy rather than antimicrobial treatment.
Patients with sepsis are generally ill and require bed rest or admission to the intensive care unit (ICU) for monitoring and treatment. Admission to an ICU or surgical ICU depends on the severity of the septic process and the degree of organ dysfunction, as well as the need for surgical intervention. Transfer to a facility able to perform diagnostic imaging tests or required surgical procedures if they are not available at the admitting hospital may be necessary.
Determine the likely source of the infection, and administer intravenous (IV) empiric antimicrobial agents until culture results become available, at which point more narrow-spectrum agents can be used (see below). In addition, offer supportive therapy aimed at maintaining organ perfusion, and provide respiratory support when necessary.[32, 38, 39]
Most patients are instructed to take nothing by mouth and can tolerate a transient decrease in caloric intake over 1-2 weeks if their fluid and electrolyte balances are maintained.
Antimicrobial Therapy
Appropriate antimicrobial therapy depends on adequate coverage of the resident flora of the organ system presumed to be the source of the septic process.[28, 29, 30, 31, 40] Agents suitable for empiric monotherapy regimens include the following:
- Imipenem
- Meropenem
- Cefoperazone (discontinued)
- Piperacillin-tazobactam
- Sulbactam-ampicillin
Combination therapeutic regimens include clindamycin or metronidazole plus levofloxacin, aztreonam, trimethoprim-sulfamethoxazole (TMP-SMZ), or an aminoglycoside.
No single drug or regimen is superior to another. Alternative agents may be used alone or in combination, provided that they have a low reactive potential and a good adverse-effect profile.[28, 29, 30, 31]
Antibiotics are normally continued until the septic process and surgical interventions have controlled the source of infection. Ordinarily, patients are treated for approximately 2 weeks. As soon as patients are able to tolerate medications orally, they may be switched to an equivalent oral antibiotic regimen in an IV-to-oral conversion program.
A Cochrane review investigated potential use of deescalation to replace empirical broad-spectrum antimicrobial treatment with narrower antimicrobial therapy.[41] This process involves either changing the agent or discontinuing combination treatment in accordance with the culture results. After examining 436 studies, the review determined that there is insufficient direct evidence to determine whether deescalation is effective or safe for adults with sepsis, severe sepsis, or septic shock. Further research using randomized, controlled trials is needed.
Empiric therapy for IV line infections
Because IV line infections are most often due to Staphylococcus aureus (methicillin-sensitive S aureus [MSSA] or methicillin-resistant S aureus [MRSA]) and less commonly due to aerobic gram-negative bacilli, the preferred empiric therapy for these infections is meropenem, cefoperazone (discontinued), or cefepime plus additional coverage for staphylococci.[12, 13] If MRSA is prevalent in the institution, add linezolid, vancomycin, or daptomycin. MRSA infection appears to carry a high risk of inadequate treatment.[42]
If coagulase-negative staphylococci are recovered from the blood (high-level bacteremia; that is, 3 or 4 positive blood cultures out of 4), avoid vancomycin for empiric therapy if possible; these are low-virulence organisms.
Treatment of coagulase-negative staphylococcal central line infection requires removal of the line. Vancomycin may be given, but central line removal is essential. If the central line cannot be removed for clinical reasons in a patient with MRSA or coagulase-negative staphylococcal infection, empiric suppressive vancomycin therapy is acceptable.
Minimize the use of vancomycin in order to prevent the emergence of Enterococcus faecium, a vancomycin-resistant species.[12]
Empiric therapy for biliary tract infections
The main biliary tract pathogens include Escherichia coli, Klebsiella species, and Enterococcus faecalis. Coverage for staphylococci and anaerobes is not needed in the biliary tract. Anaerobes are important only in patients with diabetes who have Clostridium perfringens emphysematous cholecystitis. Preferred monotherapy regimens for biliary tract infections include imipenem, meropenem, piperacillin, or cefoperazone (discontinued).
Empiric therapy for intra-abdominal and pelvic infections
The main pathogens in the lower abdomen and pelvis include aerobic coliform gram-negative bacilli and B fragilis. Enterococci do not require special coverage. Potent anti– B fragilis and aerobic gram-negative bacillary coverage are essential, in addition to surgical intervention when drainage or repair of intra-abdominal viscera is required.
Preferred monotherapy regimens for intra-abdominal and pelvic infections include imipenem, meropenem, piperacillin-tazobactam, or ampicillin-sulbactam. Preferred combination therapy for intra-abdominal and pelvic infections consists of clindamycin or metronidazole plus aztreonam, levofloxacin, or an aminoglycoside.
Empiric therapy for urosepsis
The primary uropathogens include gram-negative aerobic bacilli, such as coliforms or enterococci (E faecalis, not E faecium vancomycin-resistant enterococci). Pseudomonas aeruginosa, Enterobacter species, and Serratia species are rare uropathogens and are associated with urologic instrumentation.
Preferred monotherapy for urosepsis due to aerobic gram-negative bacilli employs aztreonam, levofloxacin, third- or fourth-generation cephalosporins, or an aminoglycoside. However, preferred monotherapy for urosepsis due to enterococci (E faecalis) involves the use of ampicillin or vancomycin (penicillin-allergic).
Empiric therapy for community-acquired urosepsis consists of levofloxacin, aztreonam, or an aminoglycoside plus ampicillin. For nosocomial urosepsis, piperacillin, imipenem, or meropenem monotherapy is preferred.
Empiric therapy for staphylococcal, pneumococcal, and meningococcal sepsis
S aureus sepsis is usually associated with infection caused by devices or acute bacterial endocarditis. Empiric therapy may be with nafcillin, an antistaphylococcal agent, a cephalosporin, a carbapenem, linezolid, or clindamycin with or without rifampin.
Pneumococcal or meningococcal sepsis may be treated with penicillin G or a beta-lactam. In patients with associated meningococcal meningitis, the antibiotic selected should penetrate the cerebrospinal fluid (CSF) and should be given in meningeal doses.
Empiric therapy for sepsis of unknown origin
The usual sources of sepsis are the distal gastrointestinal (GI) tract, the pelvis, and the genitourinary (GU) tract. Organisms that should be covered from these areas include aerobic gram-negative bacilli (coliforms) and B fragilis. Enterococci are important pathogens in biliary tract sepsis and urosepsis.
Preferred empiric monotherapy includes meropenem, imipenem, piperacillin-tazobactam, or cefoperazone (discontinued).
Empiric combination therapy includes the following:
- Levofloxacin plus either clindamycin or metronidazole
- Aztreonam
- Cefepime plus either clindamycin or metronidazole
- Ceftriaxone or aminoglycoside plus metronidazole
Outpatient management
If orally administered antibiotics are continued at home, advise the patient about possible adverse effects. If additional antimicrobial therapy is needed outside the hospital setting, it should be given orally, not intravenously. Do not allow the total course of antibiotics to exceed 3 weeks, except for the treatment of liver abscesses, which may require prolonged courses of oral antibiotics for cure or complete clinical resolution.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. Apr 2003;31(4):1250-6. [Medline].
Merrell RC. The abdomen as source of sepsis in critically ill patients. Crit Care Clin. Apr 1995;11(2):255-72. [Medline].
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. Apr 2003;31(4):1250-6. [Medline].
William BM, Corazza GR. Hyposplenism: a comprehensive review. Part I: basic concepts and causes. Hematology. Feb 2007;12(1):1-13. [Medline].
Bone RC. Sepsis and its complications: the clinical problem. Crit Care Med. Jul 1994;22(7):S8-11. [Medline].
Siegel JP, Stein KE, Zoon KC. 41 anti-endotoxin monoclonal antibodies. N Engl J Med. 1992;327:890.
Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med. Apr 23 1992;326(17):1153-7. [Medline].
Kobayashi M, Tsuda Y, Yoshida T, et al. Bacterial sepsis and chemokines. Curr Drug Targets. Jan 2006;7(1):119-34. [Medline].
[Best Evidence] Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med. May 2010;38(5):1276-83. [Medline].
Sarikonda KV, Micek ST, Doherty JA, et al. Methicillin-resistant Staphylococcus aureus nasal colonization is a poor predictor of intensive care unit-acquired methicillin-resistant Staphylococcus aureus infections requiring antibiotic treatment. Crit Care Med. Oct 2010;38(10):1991-5. [Medline].
Price CS, Hacek D, Noskin GA, et al. An outbreak of bloodstream infections in an outpatient hemodialysis center. Infect Control Hosp Epidemiol. Dec 2002;23(12):725-9. [Medline].
Cunha BA. Central intravenous line infections in the critical care unit. In: Cunha BA, ed. Infectious Diseases in Critical Care Medicine. 2nd ed. New York, NY: Informa Healthcare, Inc.; 2007:283-7/13.
Jenny-Avital ER. Catheter-related bloodstream infections. N Engl J Med. Mar 22 2007;356(12):1267; author reply 1268. [Medline].
Lange D, Zappavigna C, Hamidizadeh R, Goldenberg SL, Paterson RF, Chew BH. Bacterial Sepsis After Prostate Biopsy-A New Perspective. Urology. Oct 6 2009;[Medline].
Sacks-Berg A, Calubiran OV, Epstein HY, et al. Sepsis associated with transhepatic cholangiography. J Hosp Infect. Jan 1992;20(1):43-50. [Medline].
Girard TD, Ely EW. Bacteremia and sepsis in older adults. Clin Geriatr Med. Aug 2007;23(3):633-47, viii. [Medline].
Faro S. Sepsis in obstetric and gynecologic patients. Curr Clin Top Infect Dis. 1999;19:60-82. [Medline].
Cunha BA, Shea KW. Fever in the intensive care unit. Infect Dis Clin North Am. Mar 1996;10(1):185-209. [Medline].
Cunha BA. Sepsis and its mimics. Intern Med. 1992;13:48-55.
Sepsis and its mimics in the critical care unit. In: Cunha BA, ed. Infectious Diseases in Critical Care Medicine. 2nd Ed. New York, NY: Informa Healthcare, Inc; 2007:73-8/4.
Weinstein MP, Reller LB, Murphy JR, et al. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis. Jan-Feb 1983;5(1):35-53. [Medline].
Ristuccia PA, Hoeffner RA, Digamon-Beltran M, et al. Detection of bacteremia by buffy coat smears. Scand J Infect Dis. 1987;19(2):215-7. [Medline].
Chant C, Smith OM, Marshall JC, Friedrich JO. Relationship of catheter-associated urinary tract infection to mortality and length of stay in critically ill patients: a systematic review and meta-analysis of observational studies. Crit Care Med. May 2011;39(5):1167-73. [Medline].
Carlet J. Rapid diagnostic methods in the detection of sepsis. Infect Dis Clin North Am. Jun 1999;13(2):483-94, xi. [Medline].
Karlsson S, Heikkinen M, Pettilä V, Alila S, Väisänen S, Pulkki K, et al. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care. 2010;14(6):R205. [Medline].
van Nieuwkoop C, Bonten TN, van't Wout JW, Kuijper EJ, Groeneveld GH, Becker MJ, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care. 2010;14(6):R206. [Medline]. [Full Text].
Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: A systematic review and an economic evaluation. Crit Care Med. Jul 2011;39(7):1792-9. [Medline].
Cunha BA. Antibiotic Essentials. 5th ed. Royal Oak, Mich: Physicians Press; 2006.
Cunha BA. Antibiotic treatment of sepsis. Med Clin North Am. May 1995;79(3):551-8. [Medline].
Cunha BA. Bacteremia and sepsis. In: Rakel RE, Bope ET, eds. Conn's Current Therapy. 2003:68-75.
Cunha BA. Empiric antimicrobial therapy for bacteremia: get it right from the start or get a call from infectious disease. Clin Infect Dis. Oct 15 2004;39(8):1170-3. [Medline].
Dellinger RP. Current therapy for sepsis. Infect Dis Clin North Am. Jun 1999;13(2):495-509. [Medline].
Mackenzie I, Lever A. Management of sepsis. BMJ. Nov 3 2007;335(7626):929-32. [Medline].
Morrell MR, Micek ST, Kollef MH. The management of severe sepsis and septic shock. Infect Dis Clin North Am. Sep 2009;23(3):485-501. [Medline].
Neu HC. General Therapeutic Principles. In: Infectious Diseases. Philadelphia, Pa: WB Saunders; 1992:153.
Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. Jan 21 1999;340(3):207-14. [Medline].
Wiessner WH, Casey LC, Zbilut JP. Treatment of sepsis and septic shock: a review. Heart Lung. Sep-Oct 1995;24(5):380-92; quiz 392-3. [Medline].
Carleton SC. The cardiovascular effects of sepsis. Cardiol Clin. May 1995;13(2):249-56. [Medline].
Fuller BM, Dellinger RP. Hemodynamic resuscitation in septic shock: cardiovascular support and adjunctive therapy. Curr Infect Dis Rep. Sep 2009;11(5):357-64. [Medline].
Leibovici L, Paul M. Benefit associated with appropriate antibiotic treatment. Clin Infect Dis. Nov 15 2007;45(10):1400; author reply 1401-2. [Medline].
Gomes Silva BN, Andriolo RB, Atallah AN, Salomão R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev. Dec 8 2010;CD007934. [Medline].
Ammerlaan H, Seifert H, Harbarth S, Brun-Buisson C, Torres A, Antonelli M, et al. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis. Oct 1 2009;49(7):997-1005. [Medline].
| Associated With Sepsis (Fever ≥102°F) | Not Associated With Sepsis (Fever ≤102°F) |
| GI tract source Liver Gallbladder Colon Abscess Intestinal obstruction Instrumentation | GI tract source Esophagitis Gastritis Pancreatitis Small bowel disorders GI bleeding |
| GU tract source Pyelonephritis Intra- or perinephric abscess Renal calculi Urinary tract obstruction Acute prostatitis/abscess Renal insufficiency Instrumentation in patients with bacteriuria | GU tract source Urethritis Cystitis Cervicitis Vaginitis Catheter-associated bacteriuria (in otherwise healthy hosts without genitourinary tract disease) |
| Pelvic source Peritonitis Abscess | Upper respiratory tract source Pharyngitis Sinusitis Bronchitis Otitis |
| Lower respiratory tract source Community-acquired pneumonia (with asplenia) Empyema Lung abscess | Lower respiratory tract source Community-acquired pneumonia (in otherwise healthy host) |
| Intravascular source IV line sepsis Infected prosthetic device Acute bacterial endocarditis | Skin/soft-tissue source Osteomyelitis Uncomplicated wound infections |
| Cardiovascular source Acute bacterial endocarditis Myocardial/perivalvular ring abscess | Cardiovascular source Subacute bacterial endocarditis |
| CNS source Bacterial meningitis | |
| CNS = central nervous system; GI = gastrointestinal; GU = genitourinary; IV = intravenous. | |
| Adapted from: Cunha BA, Shea KW. Fever in the intensive care unit. Infect Dis Clin North Am. Mar 1996;10(1):185-209.[18] | |
| Clinical Presentations Mimicking Sepsis | Hemodynamic Parameters Mimicking Sepsis |
| Hemorrhage | Acute pancreatitis |
| Pulmonary embolism | Anaphylaxis |
| Myocardial infarction | Spinal cord injury |
| Pancreatitis | Adrenal insufficiency |
| Diabetic (abdominal crisis) ketoacidosis | |
| Systemic lupus erythematosus flare with abdominal crisis | |
| Ventricular pseudoaneurysm | |
| Massive aspiration/atelectasis | |
| Systemic vasculitis | |
| Diuretic-induced hypovolemia |
| Parameters | Pseudosepsis | Sepsis |
| Microbiologic | No definite source PLUS ≥1 abnormalities Negative blood cultures excluding contaminants | Proper identification/process/source PLUS ≥1 microbiologic abnormalities Positive buffy coat smear result OR 2/3 or 3/3 positive blood cultures |
| Hemodynamic | ⇓ PVR ⇑ CO | ⇓ PVR ⇑ CO Left ventricular dilatation |
| Laboratory | ⇑ WBC count (with left shift) Normal platelet count ⇑ FSP ⇑ Lactate ⇑ D-dimers ⇑ PT/PTT ⇓ Albumin ⇓ Fibrinogen ⇓ Globulins | ⇑ WBC count (with left shift) ⇓ Platelets ⇑ FSP ⇑ Lactate ⇑ D-dimers ⇑ PT/PTT ⇓ Albumin |
| Clinical | ≤102°F ± Tachycardia ± Respiratory alkalosis ± Hypotension | ≥102°F OR Hypothermia ± Mental status changes ± Hypotension |
| CO = cardiac output; FSP = fibrin split products; GI = gastrointestinal; GU = genitourinary; PT/PTT = prothrombin time/partial thromboplastin time; PVR = peripheral vascular resistance; WBC = white blood cell. | ||

